fbpx

New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030 – ResearchAndMarkets.com

The “New
Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases,
Phosphatases and GPCRs, 2018-2030” report has been added to ResearchAndMarkets.com’s
offering.

With several ongoing research initiatives and the likely approval of
multiple late stage clinical candidates, the market is expected to
witness an accelerated growth and be worth USD 5-6 billion over the
coming decade. Specifically, by 2030, close to 70% of the market is
likely to be driven by drugs targeting transcription factors, followed
by GPCRs (~18%).

The market, in the long term, is likely to be driven by five
indications, namely pancreatic cancer (36%), colorectal cancer (14%),
glioblastoma (12%), MDS (10%) and leukemia (10%). In terms of the
geographical distribution, North America and the EU5 are expected to
account for over 80% of the market.

Over 100 product candidates are currently under various stages of
development against difficult-to-modulate cancer targets. Of these, 75%
of the candidates are in preclinical / discovery stages. Amongst the
drugs that are under clinical development, 2 are in phase III, 5 in
phase II, 5 in phase I/II and 12 in phase I. Drugs in advanced clinical
evaluation (phase II and above) are napabucasin (phase III), Rigosertib
(phase III), BL-8040 (phase II), CX-01 (phase II), danvatirsen (phase
II), GI-6301 (phase II) and siG12D LODER (phase II).

About 70% of the product candidates are being developed to treat solid
tumors. Of these, pancreatic cancer (23%) is the most common; other
popular indications include breast cancer (21%), lung cancer (19%) and
colorectal cancer (16%). Further, about 30% of drugs are being developed
for the treatment of hematological malignancies, such as acute myeloid
leukemia, Burkitt lymphoma, myelodysplastic syndromes, non-Hodgkin
lymphoma and multiple myeloma.

In order to advance the development efforts, stakeholders in the
industry have forged several strategic partnerships. Over 50% of the
agreements that have been signed since 2014 were related to the conduct
of R&D activities. These were followed by licensing agreements (26%),
clinical trial collaborations (9%), and product development (6%) and
commercialization agreements (6%).

More than 80 funding instances, amounting to USD 915 million worth of
capital, have taken place in order to support R&D in this space since
2014.

Close to 70 players have designed and developed novel proprietary
technology platforms to advance R&D efforts.

Key Topics Covered

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Profiles

6. Technology Landscape

7. Publication and Grant Analysis

8. Venture Funding and Investment Analysis

9. Partnership and Collaboration Analysis

10. Market Sizing and Opportunity Analysis

11. Key Insights

12. Conclusion

13. Interview Transcripts

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

For more information about this report visit https://www.researchandmarkets.com/research/mqcg6n/new_frontiers_in?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618006071/en/